APOE and Alzheimer disease: Several studies haveexplored the potential utility of LXRs agonistsin AD therapy.13,14,17,18In vivo studies using AD-liketransgenic mouse models have revealed that LXRs agonists provoke anupregulation of ApoE and ABCA1 expression, a marked reduction in Aβlevels, enhanced brain cholesterol turnover, and reversed contextualmemory deficits.19−21 However, a major concern with LXRs agonists is thatthey not only drive up transcription of ApoE and ABCA1 but also upregulategenes associated with fatty acid synthesis.